169 related articles for article (PubMed ID: 23082005)
1. Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era.
Catena C; Colussi G; Sechi LA
Eur J Endocrinol; 2013 Jan; 168(1):C1-5. PubMed ID: 23082005
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment.
Sechi LA; Colussi G; Di Fabio A; Catena C
Am J Hypertens; 2010 Dec; 23(12):1253-60. PubMed ID: 20706195
[TBL] [Abstract][Full Text] [Related]
3. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism.
Park KS; Kim JH; Yang YS; Hong AR; Lee DH; Moon MK; Choi SH; Shin CS; Kim SW; Kim SY
Endocr J; 2017 Jun; 64(6):623-632. PubMed ID: 28458337
[TBL] [Abstract][Full Text] [Related]
4. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.
Pechère-Bertschi A; Herpin D; Lefebvre H
Ann Endocrinol (Paris); 2016 Jul; 77(3):226-34. PubMed ID: 27315759
[TBL] [Abstract][Full Text] [Related]
5. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
Riester A; Reincke M
Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism.
Fourkiotis V; Vonend O; Diederich S; Fischer E; Lang K; Endres S; Beuschlein F; Willenberg HS; Rump LC; Allolio B; Reincke M; Quinkler M;
Eur J Endocrinol; 2013 Jan; 168(1):75-81. PubMed ID: 23033260
[TBL] [Abstract][Full Text] [Related]
8. [Metabolic Outcomes of Primary Aldosteronism Patients Receiving Adrenalectomy or Spironolactone Treatments].
Xu C; Chen T; Mo D; Zhang T; Zhou F; Tian H; Ren Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 54(6):1227-1232. PubMed ID: 38162054
[TBL] [Abstract][Full Text] [Related]
9. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: Adrenal surgery.
Steichen O; Amar L; Chaffanjon P; Kraimps JL; Ménégaux F; Zinzindohoue F
Ann Endocrinol (Paris); 2016 Jul; 77(3):220-5. PubMed ID: 27297451
[TBL] [Abstract][Full Text] [Related]
10. Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy.
Nakano Y; Yoshimoto T; Fukuda T; Murakami M; Bouchi R; Minami I; Hashimoto K; Fujii Y; Kihara K; Ogawa Y
Intern Med; 2018 Sep; 57(17):2459-2466. PubMed ID: 29709927
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism.
Catena C; Colussi G; Di Fabio A; Valeri M; Marzano L; Uzzau A; Sechi LA
Horm Metab Res; 2010 Jun; 42(6):440-5. PubMed ID: 20119883
[TBL] [Abstract][Full Text] [Related]
12. A short review of primary aldosteronism in a question and answer fashion.
Farrugia FA; Zavras N; Martikos G; Tzanetis P; Charalampopoulos A; Misiakos EP; Sotiropoulos D; Koliakos N
Endocr Regul; 2018 Jan; 52(1):27-40. PubMed ID: 29453922
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of surgical and conservative treatment of patients with primary aldosteronism.
Horký K; Widimský J; Hradec E; Gregorová I; Hradec M
Exp Clin Endocrinol; 1987 Dec; 90(3):337-46. PubMed ID: 3450533
[TBL] [Abstract][Full Text] [Related]
14. Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy.
Yoneda T; Demura M; Takata H; Kometani M; Karashima S; Yamagishi M; Takeda Y
J Clin Endocrinol Metab; 2012 Apr; 97(4):1109-13. PubMed ID: 22337911
[TBL] [Abstract][Full Text] [Related]
15. Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism.
Matsuda Y; Kawate H; Matsuzaki C; Sakamoto R; Shibue K; Ohnaka K; Anzai K; Nomura M; Takayanagi R
Endocr J; 2016; 63(3):249-55. PubMed ID: 26727302
[TBL] [Abstract][Full Text] [Related]
16. Treatment of primary aldosteronism: Where are we now?
Karagiannis A
Rev Endocr Metab Disord; 2011 Mar; 12(1):15-20. PubMed ID: 21305359
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of primary aldosteronism.
Ou YC; Yang CR; Chang CL; Chang CH; Wu HC; Ho HC; Lin HS; Chang YY
Zhonghua Yi Xue Za Zhi (Taipei); 1996 Feb; 57(2):118-23. PubMed ID: 8634926
[TBL] [Abstract][Full Text] [Related]
18. Primary aldosteronism: diagnostic and treatment strategies.
Mattsson C; Young WF
Nat Clin Pract Nephrol; 2006 Apr; 2(4):198-208; quiz, 1 p following 230. PubMed ID: 16932426
[TBL] [Abstract][Full Text] [Related]
19. Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness.
Holaj R; Rosa J; Zelinka T; Štrauch B; Petrák O; Indra T; Šomlóová Z; Michalský D; Novák K; Wichterle D; Widimský J
J Hypertens; 2015 Apr; 33(4):874-82; discussion 882. PubMed ID: 25490707
[TBL] [Abstract][Full Text] [Related]
20. [Primay hyperaldosteronism--diagnostic and treatment].
Potthoff SA; Beuschlein F; Vonend O
Dtsch Med Wochenschr; 2012 Nov; 137(48):2480-4. PubMed ID: 23168980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
